IgG4-related Disease Clinical Trials
41 clinical trials for IgG4-related Disease across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases — RECRUITING · PHASE2
- The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA. — RECRUITING · PHASE2
- Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease — RECRUITING · PHASE1
- A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease — RECRUITING · PHASE2
- Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease — RECRUITING · PHASE2
- Short-term Glucocorticoid Combined with MMF for IgG4-RD — RECRUITING · NA
- Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease — RECRUITING · PHASE1
- Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease — RECRUITING · PHASE1
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO) — RECRUITING · PHASE3
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY OF INEBILIZUMAB EFFICACY AND SAFETY IN IGG4 RELATED DISEASE — RECRUITING · PHASE3
- Meir Medical Center Rheumatologic Biobank — RECRUITING
- A Prospective Cohort Study of IgG4RD in China — RECRUITING
- National Registry of IgG4-RD in China — RECRUITING
- A Study of Efgartigimod in Patients With IgG4-Related Disease — ACTIVE_NOT_RECRUITING · PHASE2
- A Study of IMM0306 in IgG4-Related Disease — NOT_YET_RECRUITING · PHASE2
- Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease — COMPLETED · NA
- Zanubrutinib in Patients With IgG4-Related Disease — COMPLETED · PHASE2
- Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) — TERMINATED · PHASE2
- A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease — ACTIVE_NOT_RECRUITING · PHASE3
- An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease — NOT_YET_RECRUITING · PHASE1
- A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease — ACTIVE_NOT_RECRUITING · PHASE3
- OPEN-LABEL, UNCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF INEBILIZUMAB IN CHILDREN FROM 2 YEARS TO LESS THAN 18 YEARS OF AGE WITH IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) — COMPLETED
- A RANDOMIZED, PHASE 3, DOUBLE-BLIND, 52-WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILZABRUTINIB (SAR444671) COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH ACTIVE IGG4-RELATED DISEASE — NOT_YET_RECRUITING · PHASE3
- Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease — ACTIVE_NOT_RECRUITING
- Deciphering B and T cell Co-stimulation for the Targeted Treatment of IgG4-Related Disease — TERMINATED · PHASE2
- Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases — OTHER · NA
- Study of Sirolimus in IgG4-related Disease — NOT_YET_RECRUITING · NA
- Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease — OTHER · NA
- Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients — COMPLETED
- Tofatib Treatment for IgG4-related Disease — OTHER
- Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis — COMPLETED
- Safety and Efficacy of Abatacept in IgG4-Related Disease — COMPLETED · PHASE2
- Characterizing IgG4-RD With 68Ga-FAPI PET/CT — OTHER · PHASE1
- Belimumab Treatment for IgG4-related Disease — OTHER · PHASE4
- AN OPEN LABEL, TWO-ARM, PHASE 2A STUDY TO EVALUATE THE EFFECT OF RILZABRUTINIB (PRN1008/SAR444671) ON SAFETY AND DISEASE ACTIVITY IN PATRTICIPANTS WITH IGG4-RELATED DISEASE — COMPLETED · PHASE2
- Treatment of IgG4-Related Disease With Revlimid and Rituximab — COMPLETED · PHASE1
- Infraorbital Nerve Involvement on Magnetic Resonance Imaging in IgG4-related Ophthalmic Disease — COMPLETED
- To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom — OTHER · PHASE4
- Plasmablast Detection From IgG4-Related Disease Patients — OTHER
- A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood — OTHER · NA
- Glucocorticoids in Patients With IgG4-RD — OTHER · PHASE2
Refine this search